Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 40

The DOI matches its Crossref record.

Sepsis in the Severely Immunocompromised Patient

Kalil, Andre C., Opal, Steven M. · 2015 · Current Infectious Disease Reports

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11908-015-0487-4

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 79

  1. Angus DC, van der Poll T. Severe sepsis and septic shock. 2013; 369: 840-852. · DOI · Paper page
  2. Legrand M, Max A, Peigne V, et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med. 2012;40(1):43–9. · DOI · Paper page
  3. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):e56–93. · DOI · Paper page
  4. Kern WV. Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis. 2006;42(2):533–40. · DOI
  5. Jeddi R, Achour M, Amor RB, et al. Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes. Hematology. 2010;15(1):23–32. · doi:10.1179/102453310x12583347009577
  6. Kalil AC, Syed A, Rupp ME, et al. Is bacteremic sepsis associated with higher mortality in transplant recipients than in nontransplant patients? A matched case-control propensity-adjusted study. Clin Infect Dis. 2015;60(2):216–22. This study compared patients who had a solid organ transplant and sepsis to patients who did not have organ transplant but had sepsis. They were matched by age, gender, and hospital unit location at the time of blood culture collection. The results showed a statistically significant higher survival rates for septic patients who had organ transplantation than that those without transplantation, after accounting for disease severity and co-morbidities. · DOI
  7. Penack O, Becker C, Buchheidt M, et al. Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases working party of the German Society of Hematology and Medical Oncology. Ann Hematol. 2014;93(7):1083–95. This evidence-based review is the most recent national set of guidelines established as a set of recommendations to manage the febrile neutropenic patient. The guideline favors early antibiotic therapy directed towards the most likely pathogens with appropriate therapy guided by local susceptibilty patterns of common bacterial pathogens. · DOI
  8. Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan. Clin Infect Dis. 2004;39 Suppl 1:S49. · DOI
  9. Viscoli C on behalf of the EORTC international antimicrobial therapy group. Management of infection in cancer patients. Euro J Cancer. 2002;38 suppl 4:82–7.
  10. Legrand M, Max A, Schlemmer B, Azoulay E, Gachot B. The strategy of antibiotic use in critically ill neutropenic cancer patients. Ann Intensive Care. 2011;1:1–22. · DOI · Paper page
  11. Hanberger H, Giske CG, Giamarello H. When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock. Curr Infect Dis Rep. 2011;31(5):416–25. · DOI
  12. Pop-Vicas A, Opal SM. The clinical impact of multidrug resistant gram-negative bacilli in the management of septic shock. Virulence. 2014;5(1):1–7. This review paper discusses the problem of multidrug resistant bacterial pathogens and provides some recommendations on how to treat these infections in criticall ill patients. · DOI
  13. Dellinger RP, Levy MM, Rhodes A, et al. The surviving sepsis guidelines: 2012. Crit Care Med. 2013;41:580–637. · DOI · Paper page
  14. Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association of supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–51. · DOI · Paper page
  15. Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975;135:715–9. · doi:10.1001/archinte.1975.00330050089015 · Paper page
  16. Sepkowitz KA. Treatment of patients with hematologic neoplasm, fever, neutropenia. Clin Infect Dis. 2005;40 suppl 4:S253–256. · doi:10.1086/427330
  17. Rolston KV. Challenges in the treatment of gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis. 2005;40 suppl 4:S246–252. · DOI
  18. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986;315:552–8. · DOI · Paper page
  19. Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev. 2003;(3):CD003038. · DOI
  20. Vardakas KZ, Samonis G, Chrysanthopoulou SA, et al. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomized controlled trials. Lancet Infect Dis. 2005;5(7):431–9. · DOI
  21. Paul M, Dickstein Y, Borok S, et al. Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic with cancer. Cochrane Database Syst Rev. 2014;1:CD003914. This systematic review finds that the addition of empiric antibiotics that target gram-positive bacterial pathogens does not result in improved survival rates in febrile neutropenic patients when compared to antibacterial regimens that initiate coverage of these pathogens only after their presence are documented by bacterial cultures.
  22. Bow EJ. Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin Hematol. 2009;46:259–68. · DOI
  23. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–226. · DOI · Paper page
  24. Bosmann M, Ward PA. The inflammatory response in sepsis. Trends Immunol. 2013;34:129–36. · DOI · Paper page
  25. Opal SM, van der Poll T. Endothelial barrier dysfunction in septic shock. J Intern Med. 2014. doi: 10.1111./joim.12331 . This basic review details the nature of the endothelial barrier in the microcirculation and the factors that disupt the barrier function in septic shock. New molecular targets have been recently identified that might offer new treatment options for immunocompromised patients with septic shock.
  26. Skvarc M, Stubjar D, Rogina P, Kaasch AJ. Non-culture-based methods to diagnose bloodstream infections: does it work? Eur J Microbiol Immunol. 2013;3(2):97–104. · DOI
  27. Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7:338–48. · DOI · Paper page
  28. Kim PM, Wu YT, Cooper C, et al. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis. 2010;51:381–9. · doi:10.1086/655131
  29. Kalil AC. Is cefepime safe for clinical use? A Bayesian viewpoint. J Antimicrob Chemother. 2011;66:1207–9. · doi:10.1093/jac/dkr138
  30. Carlet J, Cohen J, Calandra T, Opal SM, Masur H. Sepsis, time to reconsider the concept. Crit Care Med. 2008;36(3):964–7. · DOI
  31. Vincent J-L, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet. 2013;381:774–5. · DOI · Paper page
  32. Opal SM, Dellinger RP, Vincent J-L, Masur H, Angus DC. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C? Crit Care Med. 2014;42:1714–21. This clinical review discusses the difficulties encountered in the study of new anti-sepsis drugs in clinical trials and offers some suggestions on how to improve future clinical trials. · DOI · Paper page
  33. Deutchman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity. 2014;40:463–75. This is an excellent review of the current understanding of the molecular mechanisms that result in septic shock and offers some new ways to address the problem from a mechanistic perspective. · DOI · Paper page
  34. Gomez H, Ince C, DeBacker D, Pickkers P, Payen D, Hotchkiss J, et al. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock. 2014;41(1):3–11. This basic review argues that the problem of sepsis at the cellular level is that cells functionallly loose their ability to maintain their specialized functions in tissues and retreat into a de-differentiated state for individual cell survival. · DOI · Paper page
  35. Mehta D, Ravindran K, Kuebler W. Novel regulators of endothelial barrier function. Am J Physiol Lung Cell Mol Physiol. 2014;307:L924–35. This paper reviews the structure and function of intercellular gap junctions between endothelial cells in health and disease. · DOI
  36. Kumar A, Paladugu B, Haery C, et al. Timing of antibiotic administration in relation to duration of shock is a critical determinant of survival in a murine model of E. coli sepsis: association with serum lactate and inflammatory cytokines. J Infect Dis. 2006;193:251–8. · DOI · Paper page
  37. Hotchkiss RS, Opal SM. Immunotherapy for sepsis: a new approach against an ancient foe. N Engl J Med. 2010;363(1):87–9. · DOI · Paper page
  38. Chahin A, Opal S, Zorzopulos J, et al. The novel immunotherapeutic oligodeoxynucleotide IMT504 protects neutropenic animals from fatal Pseudomonas aeruginosa bacteremia and sepsis. Antimicrob Agents Chemother. 2015;59(2):1225–9. This experimental study demonstrates that specific short sequences of oligonucleotides can function as immunostimulants and improve the prognosis of experimental animals with febrile neutropenic systemic infections. Whether this strategy will work in neutropenic sepsis remains to be tested in clinical trials. · DOI
  39. Kalil AC, Dakroub H, Freifeld AG. Sepsis and solid organ transplantation. Curr Drug Targets. 2007;8(4):533–41. · doi:10.2174/138945007780362746
  40. Trzeciak S, Sharer R, Piper D, et al. Infections and severe sepsis in solid-organ transplant patients admitted from a university-based ED. The Am J Emergency Med. 2004;22(7):530–3. · doi:10.1016/j.ajem.2004.09.010
  41. Hsu RB, Chang CI, Fang CT, Chang SC, Wang SS, Chu SH. Bloodstream infection in heart transplant recipients: 12-year experience at a university hospital in Taiwan. Euro J Cardio-Thoracic Surg. 2011;40(6):1362–7.
  42. Candel FJ, Grima E, Matesanz M, et al. Bacteremia and septic shock after solid-organ transplantation. Transplantation Proc. 2005;37(9):4097–9. · doi:10.1016/j.transproceed.2005.09.181
  43. Wan Q, Ye Q, Zhou J. Mortality predictors of bloodstream infections in solid-organ transplant recipients. Exp Clin Trans. 2013;11(3):211–4. · doi:10.6002/ect.2012.0093
  44. Bodro M, Sabe N, Tubau F, et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation. 2013;96(9):843–9. This study analyzed a cohort of solid organ transplant patients who developed bacteremia with ESKAPE organisms and concluded that the following factors were independently associated with ESKAPE infection: prior transplantation, septic shock, and prior antibiotic therapy. · DOI · Paper page
  45. Linares L, Garcia-Goez JF, Cervera C, Almela M, Sanclemente G, Cofan F, et al. Early bacteremia after solid organ transplantation. Trans Proc. 2009;41(6):2262–4. · DOI
  46. Malinis MF, Mawhorter SD, Jain A, Shrestha NK, Avery RK, van Duin D. Staphylococcus aureus bacteremia in solid organ transplant recipients: evidence for improved survival when compared with nontransplant patients. Transplantation. 2012;93(10):1045–50. · DOI
  47. Shoham S, Marr KA. Invasive fungal infections in solid organ transplant recipients. Future Microbiol. 2012;7(5):639–55. · DOI · Paper page
  48. van Hal SJ, Marriott DJ, Chen SC, Nguyen Q, Sorrell TC, Ellis DH, et al. Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience. Trans Infect Dis. 2009;11(2):122–7. · DOI
  49. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005;143(12):870–80. · DOI · Paper page
  50. Chuang P, Parikh CR, Langone A. Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers. Clin Trans. 2005;19(2):230–5. · DOI · Paper page
  51. Schmaldienst S, Dittrich E, Horl WH. Urinary tract infections after renal transplantation. Curr Opin Urol. 2002;12(2):125–30. · doi:10.1097/00042307-200203000-00007
  52. Wagener MM, Yu VL. Bacteremia in transplant recipients: a prospective study of demographics, etiologic agents, risk factors, and outcomes. Am J Infect Control. 1992;20(5):239–47. · doi:10.1016/s0196-6553(05)80197-x
  53. Warren JW, Platt R, Thomas RJ, Rosner B, Kass EH. Antibiotic irrigation and catheter-associated urinary-tract infections. N Engl J Med. 1978;299(11):570–3. · DOI · Paper page
  54. Koneru B, Selby R, O’Hair DP, Tzakis AG, Hakala TR, Starzl TE. Nonobstructing colonic dilatation and colon perforations following renal transplantation. Arch Surg. 1990;125(5):610–3. · doi:10.1001/archsurg.1990.01410170056012
  55. Andreoni KA, Pelletier RP, Elkhammas EA, et al. Increased incidence of gastrointestinal surgical complications in renal transplant recipients with polycystic kidney disease. Transplantation. 1999;67(2):262–6. · doi:10.1097/00007890-199901270-00013
  56. Dominguez Fernandez E, Albrecht KH, et al. Prevalence of diverticulosis and incidence of bowel perforation after kidney transplantation in patients with polycystic kidney disease. Transpl Int. 1998;11(1):28–31. · DOI
  57. Abbott KC, Oliver 3rd JD, Hypolite I, et al. Hospitalizations for bacterial septicemia after renal transplantation in the United States. Am J Nephrol. 2001;21(2):120–7. · doi:10.1159/000046234
  58. Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine. 1988;67(2):132–43. · DOI · Paper page
  59. George DL, Arnow PM, Fox AS, et al. Bacterial infection as a complication of liver transplantation: epidemiology and risk factors. Rev Infect Dis. 1991;13(3):387–96. · DOI · Paper page
  60. Koivusalo A, Isoniemi H, Salmela K, Hockerstedt K. Biliary complications in 100 adult liver transplantations: a retrospective clinical study. Transpl Int. 1994;7 Suppl 1:S119–20. · doi:10.1111/j.1432-2277.1994.tb01327.x
  61. Collins LA, Samore MH, Roberts MS, Luzzati R, Jenkins RL, Lewis WD, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis. 1994;170(3):644–52. · DOI · Paper page
  62. Paya CV, Hermans PE, Washington 2nd JA, et al. Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clinic Proc. 1989;64(5):555–64. · DOI · Paper page
  63. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev. 1997;10(1):86–124. · DOI · Paper page
  64. Newell KA, Millis JM, Arnow PM, et al. Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation. Transplantation. 1998;65(3):439–42. · doi:10.1097/00007890-199802150-00027
  65. Tachopoulou OA, Vogt DP, Henderson JM, Baker M, Keys TF. Hepatic abscess after liver transplantation: 1990-2000. Transplantation. 2003;75(1):79–83. · doi:10.1097/00007890-200301150-00014
  66. Hsu JL, Enser JJ, McKown T, et al. Outcomes of Clostridium difficile infection in recipients of solid abdominal organ transplants. Clin Trans. 2014;28(2):267–73. This study evaluated solid organ transplant patients who developed Clostridium difficile infection and found that the risk factors for clinical failure at 14 days were vasopressor support, previous Clostridium difficile infection, and treatment with vancomycin. Three-quarters of all transplant patients were clinically cured at 14 days. · doi:10.1111/ctr.12309
  67. Tsapepas DS, Martin ST, Miao J, et al. Clostridium difficile infection, a descriptive analysis of solid organ transplant recipients at a single center. Diagn Microbiol Infect Dis. 2014;80(4):239–344
  68. Corensek MJ, Stewart RW, Keys TF, Mehta AC, McHenry MC, Goormastic M. A multivariate analysis of risk factors for pneumonia following cardiac transplantation. Transplantation. 1988;46(6):860–5. · DOI
  69. Cisneros JM, Munoz P, Torre-Cisneros J, et al. Pneumonia after heart transplantation: a multi-institutional study. Spanish Transplantation Infection Study Group. Clin Infect Dis. 1998;27(2):324–31. · DOI
  70. Myers TJ, Khan T, Frazier OH. Infectious complications associated with ventricular assist systems. ASAIO J. 2000;46(6):S28–36. · DOI
  71. Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis. 2001;33(5):629–40. · DOI · Paper page
  72. Hofflin JM, Potasman I, Baldwin JC, Oyer PE, Stinson EB, Remington JS. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med. 1987;106(2):209–16. · doi:10.7326/0003-4819-106-2-209
  73. Horvath J, Dummer S, Loyd J, Walker B, Merrill WH, Frist WH. Infection in the transplanted and native lung after single lung transplantation. Chest. 1993;104(3):681–5. · DOI
  74. Kramer MR, Marshall SE, Starnes VA, Gamberg P, Amitai Z, Theodore J. Infectious complications in heart-lung transplantation. Analysis of 200 episodes. Arch Intern Med. 1993;153(17):2010–6. · doi:10.1001/archinte.1993.00410170090009
  75. Maurer JR, Tullis DE, Grossman RF, Vellend H, Winton TL, Patterson GA. Infectious complications following isolated lung transplantation. Chest. 1992;101(4):1056–9. · doi:10.1378/chest.101.4.1056
  76. Hadjiliadis D, Sporn TA, Perfect JR, Tapson VF, Davis RD, Palmer SM. Outcome of lung transplantation in patients with mycetomas. Chest. 2002;121(1):128–34. · DOI
  77. Smith PC, Slaughter MS, Petty MG, Shumway SJ, Kshettry VR, Bolman RM, 3rd. Abdominal complications after lung transplantation. J Heart Lung Transplantation 1995;14:44–51
  78. Venuta F, Boehler A, Rendina EA, et al. Complications in the native lung after single lung transplantation. Euro J Cardio-Thoracic Surg. 1999;16(1):54–8. · DOI
  79. Stewart S, McNeil K, Nashef SA, Wells FC, Higenbottam TW, Wallwork J. Audit of referral and explant diagnoses in lung transplantation: a pathologic study of lungs removed for parenchymal disease. J Heart Lung Trans. 1995;14(6 Pt 1):1173–86.

Cited by

See all 40

Metadata

Authors
Kalil, A. C., & Opal, S. M.
Venue
Current Infectious Disease Reports
Published
2015-05-05
Volume
17
Issue
6
ISSN
  • 1523-3847
  • 1534-3146
Cited by
40
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sepsis in the Severely Immunocompromised Patient. https://app.cochat.ai/papers/10.1007/s11908-015-0487-4
The paper
Kalil, A. C., & Opal, S. M. (2015). Sepsis in the Severely Immunocompromised Patient. Current Infectious Disease Reports. https://doi.org/10.1007/s11908-015-0487-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.